Skip to main content
SpringerLink
Log in

Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

This report examines the prognostic associations between QOL scores measured by the EORTC QLQ-C30 and survival in a large heterogeneous population of cancer patients. Eight hundred and fifty-one cancer patients who were to receive chemotherapy were enrolled in two National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) antiemetic trials. All patients completed the EORTC QLQ-C30 immediately prior to their first chemotherapy. Survival data were available and obtained for 474 of 639 patients (74%). Cox's proportional hazards model was used to assess the independent impact of QOL and demographic variables on survival. Presence of metastatic disease, diagnosis of lung or ovarian cancer, ECOG performance status, global quality of life and emotional functioning were significantly associated with survival. Global QOL was predictive in all patients, in subgroups of patients with metastatic disease, with breast and lung cancer and other tumour types. In patients with low global quality of life scores, patients with low emotional functioning ratings lived longer than did patients with high emotional functioning ratings. Patients with high global QOL live significantly longer than do patients with low global QOL. The relationship between emotional functioning in patients with low global QOL and survival needs confirmation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. Radiother Oncol 1989; 15: 235-242.

    Article  CAS  PubMed  Google Scholar 

  2. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991; 67: 3131-3135.

    Article  CAS  PubMed  Google Scholar 

  3. Ruckdeschel JC, Piantidosi S. Quality of life in lung cancer surgical adjuvant trials. Chest 1994; 106(Suppl 6): 3245-3255.

    Google Scholar 

  4. Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in Phase II Trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 1995; 87: 1316-1322.

    Article  CAS  PubMed  Google Scholar 

  5. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833-1838.

    Article  CAS  PubMed  Google Scholar 

  6. Coates A, Thomson D, McLeod DRM, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29A: 1731-1734.

    Article  CAS  PubMed  Google Scholar 

  7. Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of Ondansetron combined with Dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-1057.

    Article  CAS  PubMed  Google Scholar 

  8. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3: 307-312.

    Article  CAS  PubMed  Google Scholar 

  9. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international trials inoncology. JNatl Cancer Inst 1993; 85: 365-376.

    Article  CAS  Google Scholar 

  10. Osoba D, Zee B, Pater JL, et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.

    Article  CAS  PubMed  Google Scholar 

  11. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Royal Stat Soc 1972 Series A; 135: 185-207.

    Article  Google Scholar 

  12. Addington-Hall JM, MacDonald LD, Anderson HR. Can the Spitzer quality of life index help to reduce prognostic uncertainty in terminal care? Br J Cancer 1990; 62: 695-699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984; 2: 472-483.

    Article  CAS  PubMed  Google Scholar 

  14. Coates AS, Fischer Dillenbeck C, McNeil DR, et al. On the receiving end - II. Linear analog self assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633-1637.

    Article  CAS  PubMed  Google Scholar 

  15. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL index for use by physicians. J Chron Dis 1981; 34: 585-597.

    Article  CAS  PubMed  Google Scholar 

  16. Derogatis LR, Abeloff MD, Melisaratos N. Psychological copingmechanisms and survival time inmetastatic breast cancer. JAMA 1979; 242: 1504-1508.

    Article  CAS  PubMed  Google Scholar 

  17. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome. Lancet 1979; 2(8146):785–787.

    Article  CAS  PubMed  Google Scholar 

  18. Kubler-Ross E. On Death and Dying. New York, NY (USA): Macmillan, 1969.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada

    J. Dancey, B. Zee, M. Whitehead, F. Lu, J. Latreille & J. L. Pater

  2. British Columbia Cancer Agency and University of British Columbia, Vancouver, Canada

    D. Osoba

  3. Credit Valley Hospital and University of Toronto, Mississauga, Canada

    L. Kaizer

Authors
  1. J. Dancey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Zee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Osoba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Whitehead
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Kaizer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Latreille
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. L. Pater
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dancey, J., Zee, B., Osoba, D. et al. Quality of life scores: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 6, 151–158 (1997). https://doi.org/10.1023/A:1026442201191

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026442201191

Search

Navigation